Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831943 | 1.00 | HSD17B10 (0.75) | HSD17B10MEN1KMT2AAPLNRPTGS1 | |
| Hydrochloric Acid SCHEMBL2527027 | 0.98 | HSD17B10 (0.73) | HSD17B10MEN1KMT2AAPLNRPTGS1 | |
| SCHEMBL23229043 | 0.87 | HSD17B10 (0.62) | HSD17B10MEN1KMT2APTGS1AKR1C3 | |
| SCHEMBL267732 | 0.86 | CYP3A4 (0.62) | HSD17B10MEN1KMT2AAPLNRALDH1A1 | |
| SCHEMBL504029 | 0.86 | HSD17B10 (1.00) | HSD17B10MEN1KMT2APTGS1AKR1C3 | |
| SCHEMBL29392677 | 0.86 | CYP3A4 (0.62) | HSD17B10MEN1KMT2AAPLNRALDH1A1 | |
| SCHEMBL30512021 | 0.86 | HSD17B10 (1.00) | HSD17B10MEN1KMT2APTGS1AKR1C3 | |
| SCHEMBL6175515 | 0.85 | CAMK2A (0.68) | HSD17B10MEN1KMT2APTGS1AKR1C3 | |
| SCHEMBL23229241 | 0.84 | HSD17B10 (0.59) | HSD17B10MEN1KMT2APTGS1AKR1C3 | |
| SCHEMBL11577618 | 0.84 | HSD17B10 (0.63) | HSD17B10MEN1KMT2APTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103030647-B | Method for synthesizing glabridin | SHANDONG ANALYSIS TEST CENTER (CN) | 2014-10-29 | — | — | CN | claimed |
| WO-2005054169-A1 | PREPARATION METHOD OF 2-PHENYLACETOPHENONE DERIVATIVES | HANBUL COSMETIC CO., LTD. (KR) | 2005-06-16 | — | — | WO | claimed |
| CN-112682031-B | Oil field interwell tracer, tracing method and fracturing fluid | 中国石油化工股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-117964633-B | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117964633-B | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117964633-A | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964633-A | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3157938-B1 | HETERO FUNCTIONAL BINDING SYSTEMS | ANTEO TECH PTY LTD (AU) | 2022-03-16 | — | — | EP | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-112682031-A | Oil field interwell tracer, tracing method and fracturing fluid | 中国石油化工股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5470854-A | Antiestrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-28 | — | — | US | disclosed |
| US-5464788-A | Stopping labor | MERCK & CO., INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1995025443-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0516257-A1 | Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-02 | — | — | EP | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
| US-4493823-A | USING CARBOXYBENZENE COMPOUND | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | HSD17B10 368/4885MEN1 2645/4885KMT2A 2804/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HSD17B10 368/4885MEN1 2645/4885KMT2A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.